Mercados españoles cerrados

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
150,26-0,92 (-0,61%)
Al cierre: 4:00PM EDT

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin 4
Ireland
353 1 634 7800
http://www.jazzpharma.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo1.620

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Bruce C. CozaddCo-Founder, Chairman & CEO2,33MN/A1964
Mr. Daniel N. Swisher Jr.Pres & COO1,24MN/A1963
Ms. Neena M. Patil J.D.Sr. VP & Gen. Counsel331,61kN/A1975
Dr. Robert Iannone M.D.Exec. VP of R&D771,48kN/A1967
Ms. Renée D. GaláExec. VP & CFON/AN/A1972
Ms. Patricia CarrVP of Fin. & Principal Accounting OfficerN/AN/A1971
Dr. Finbar Larkin Ph.D.Sr. VP of Technical OperationsN/AN/A1958
Dr. Katherine A. LittrellVP of Investor RelationsN/AN/AN/A
Ms. Heidi MannaSr. VP & Chief HR OfficerN/AN/AN/A
Ms. Karen J. WilsonSr. VP of Fin.N/AN/A1963
Los importes son a partir de 31 de diciembre de 2019 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.

Gobierno corporativo

El ISS Governance QualityScore de Jazz Pharmaceuticals plc, a día 6 de octubre de 2020, es 5. Las puntuaciones base son Auditoría: 1; Tablero: 5; Derechos de los accionistas: 5; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.